Linked Life Data

8998256

Source:http://linkedlifedata.com/resource/pubmed/id/8998256

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12 Pt 1
pubmed:dateCreated
1997-1-17
pubmed:abstractText
Insulin influences platelet function by reducing platelet responsiveness to vasoactive agonists. In hypertension these insulin-related inhibitory effects are blunted. The aim of this study was to determine whether platelet sensitivity to insulin is affected after 12 weeks of antihypertensive treatment with calcium channel blockers. Eleven patients with essential hypertension and non-insulin-dependent diabetes were treated with either isradipine or diltiazem. Platelet free calcium concentration was measured spectrofluorometrically in nonstimulated and in angiotensin II (1 nmol/L)-stimulated platelets that had been pre-exposed to insulin (70 microU/mL). Platelets were studied before therapy and after 12 weeks of treatment. Systolic blood pressure and mean arterial pressure decreased significantly during treatment. Both calcium channel blockers equally decreased fasting serum insulin levels (from 138 +/- 2.7 pmol/L before therapy to 106 +/- 9.9 pmol/L after therapy). Results with both calcium channel antagonists were similar and have been pooled. In the pretreatment phase, insulin pre-incubation had no effect on angiotensin II-stimulated intracellular free calcium and responses to angiotensin II were similar in the absence (265 +/- 10.5 nmol/L) and presence of insulin (233 +/- 12.1 nmol/L). After treatment with calcium channel blockers, insulin significantly (P < .001) reduced angiotensin II-induced rise of intracellular free calcium from 214 +/- 7.7 nmol/L (absence of insulin) to 153 +/- 9.3 nmol/L (presence of insulin). Whether these effects are due specifically to calcium channel blockers or whether they are the result of lowering of blood pressure remains unclear. Serum insulin levels were positively correlated with angiotensin II-stimulated increase in intracellular free calcium in platelets pre-exposed to insulin, (r = 0.46; P < .05) suggesting that with increasing levels of insulin resistance, the inhibitory effects of insulin are reduced. This study shows that treatment of non-insulin-dependent diabetic hypertensive patients with these calcium channel blockers reduces hyperinsulinemia and increases sensitivity of platelets to the inhibitory effect of insulin on angiotensin II-stimulated calcium responses.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0895-7061
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1214-21
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:8998256-Angiotensin II, pubmed-meshheading:8998256-Antihypertensive Agents, pubmed-meshheading:8998256-Blood Platelets, pubmed-meshheading:8998256-Blood Pressure, pubmed-meshheading:8998256-Calcium, pubmed-meshheading:8998256-Calcium Channel Blockers, pubmed-meshheading:8998256-Diabetes Mellitus, Type 2, pubmed-meshheading:8998256-Diltiazem, pubmed-meshheading:8998256-Double-Blind Method, pubmed-meshheading:8998256-Female, pubmed-meshheading:8998256-Humans, pubmed-meshheading:8998256-Hypertension, pubmed-meshheading:8998256-Hypoglycemic Agents, pubmed-meshheading:8998256-Insulin, pubmed-meshheading:8998256-Insulin Resistance, pubmed-meshheading:8998256-Isradipine, pubmed-meshheading:8998256-Male, pubmed-meshheading:8998256-Middle Aged, pubmed-meshheading:8998256-Vasoconstrictor Agents
pubmed:year
1995
pubmed:articleTitle
Treatment of non-insulin-dependent diabetic hypertensive patients with Ca2+ channel blockers is associated with increased platelet sensitivity to insulin.
pubmed:affiliation
Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't